COVID-19 vaccine developed by China's CanSino to continue advancing phase-3 trials: report
BEIJING - China's CanSino Biologics Inc has got green light to continue phase-3 trials of its COVID-19 vaccine with the support of findings of an independent data monitoring committee, said recent media reports.
The independent committee "found the drugmaker's COVID-19 vaccine met its pre-specified primary safety and efficacy targets under an interim analysis of phase-3 trial data," Reuters cited the biopharmaceutical company to report on Monday.
"No adverse events related to the vaccine had occurred," the report said.
The vaccine candidate, referred to as Ad5-nCoV, is developed by CanSino Biologics Inc and the Academy of Military Sciences in China.
CanSino was approved to conduct phase-3 clinical trials in some countries in Europe and Asia, Wu Yuanbin, an official with China's Ministry of Science and Technology, said in September last year.
- Key schools to launch low-altitude economy major
- Mainland scholar discloses fallacies in Lai's separatist narrative on 'unity'
- University's expulsion of female student ignites online debate
- 4,000 hiking enthusiasts hit rugged trails in Chongqing
- Creative fireworks show held in China's 'fireworks capital'
- Chinese scientists achieve net-negative greenhouse gas emissions via electrified catalysis
